| Year |
Citation |
Score |
| 2024 |
Snacel-Fazy E, Soubéran A, Grange M, Joseph K, Colin C, Morando P, Luche H, Pagano A, Brustlein S, Debarbieux F, Toutain S, Siret C, van de Pavert SA, Rougon G, Figarella-Branger D, et al. SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment. Cell Death & Disease. 15: 676. PMID 39278921 DOI: 10.1038/s41419-024-07056-z |
0.45 |
|
| 2024 |
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances. 6: vdae038. PMID 38590763 DOI: 10.1093/noajnl/vdae038 |
0.807 |
|
| 2023 |
Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, et al. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. Ebiomedicine. 95: 104752. PMID 37572644 DOI: 10.1016/j.ebiom.2023.104752 |
0.588 |
|
| 2023 |
Baeza-Kallee N, Bergès R, Hein V, Cabaret S, Garcia J, Gros A, Tabouret E, Tchoghandjian A, Colin C, Figarella-Branger D. Deciphering the Action of Neuraminidase in Glioblastoma Models. International Journal of Molecular Sciences. 24. PMID 37511403 DOI: 10.3390/ijms241411645 |
0.792 |
|
| 2023 |
Métais A, Tauziède-Espariat A, Garcia J, Appay R, Uro-Coste E, Meyronet D, Maurage CA, Vandenbos F, Rigau V, Chiforeanu DC, Pallud J, Senova S, Saffroy R, Colin C, Edjlali M, et al. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion. Acta Neuropathologica Communications. 11: 14. PMID 36647073 DOI: 10.1186/s40478-023-01506-z |
0.447 |
|
| 2022 |
Catanzaro G, Besharat ZM, Carai A, Jäger N, Splendiani E, Colin C, Po A, Chiacchiarini M, Citarella A, Gianno F, Cacchione A, Miele E, Diomedi Camassei F, Gessi M, Massimi L, et al. MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. Biomarker Research. 10: 44. PMID 35715818 DOI: 10.1186/s40364-022-00389-x |
0.436 |
|
| 2022 |
Figarella-Branger D, Colin C, Baeza-Kallee N, Tchoghandjian A. A2B5 Expression in Central Nervous System and Gliomas. International Journal of Molecular Sciences. 23. PMID 35563061 DOI: 10.3390/ijms23094670 |
0.767 |
|
| 2022 |
Appay R, Bielle F, Sievers P, Barets D, Fina F, Boutonnat J, Adam C, Gauchotte G, Godfraind C, Lhermitte B, Maurage CA, Meyronet D, Mokhtari K, Rousseau A, Tauziède-Espariat A, ... ... Colin C, et al. Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours. Neuropathology and Applied Neurobiology. e12813. PMID 35293634 DOI: 10.1111/nan.12813 |
0.442 |
|
| 2022 |
Chanez B, Appay R, Guille A, Lagarde A, Colin C, Adelaide J, Denicolai E, Jiguet-Jiglaire C, Bequet C, Graillon T, Boissonneau S, Nanni-Metellus I, Dufour H, Figarella-Branger D, Chinot O, et al. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy. Journal of the Neurological Sciences. 436: 120207. PMID 35259554 DOI: 10.1016/j.jns.2022.120207 |
0.765 |
|
| 2021 |
Figarella-Branger D, Appay R, Metais A, Tauziède-Espariat A, Colin C, Rousseau A, Varlet P. [The 2021 WHO classification of tumours of the central nervous system]. Annales De Pathologie. PMID 34865882 DOI: 10.1016/j.annpat.2021.11.005 |
0.51 |
|
| 2021 |
Métais A, Appay R, Pagès M, Gallardo C, Silva K, Siegfried A, Perbet R, Maurage CA, Scavarda D, Fina F, Uro-Coste E, Riffaud L, Colin C, Figarella-Branger D. Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: the diagnostic challenges. Neuropathology and Applied Neurobiology. PMID 34551121 DOI: 10.1111/nan.12769 |
0.42 |
|
| 2021 |
Pages M, Uro-Coste E, Colin C, Meyronet D, Gauchotte G, Maurage CA, Rousseau A, Godfraind C, Mokhtari K, Silva K, Figarella-Branger D, Varlet P, On Behalf Of The Renoclip-Loc Network. The Implementation of DNA Methylation Profiling into a Multistep Diagnostic Process in Pediatric Neuropathology: A 2-Year Real-World Experience by the French Neuropathology Network. Cancers. 13. PMID 33803647 DOI: 10.3390/cancers13061377 |
0.426 |
|
| 2021 |
Barets D, Appay R, Heinisch M, Battistella M, Bouvier C, Chotard G, Le Loarer F, Macagno N, Perbet R, Pissaloux D, Rousseau A, Tauziède-Espariat A, Varlet P, Vasiljevic A, Colin C, et al. Specific and Sensitive Diagnosis of -ITD in Various Cancers by Digital PCR. Frontiers in Oncology. 11: 645512. PMID 33718245 DOI: 10.3389/fonc.2021.645512 |
0.645 |
|
| 2020 |
Appay R, Fina F, Barets D, Gallardo C, Nanni-Metellus I, Scavarda D, Henaff D, Vincent J, Grewis L, Pourquier P, Colin C, Figarella-Branger D. Multiplexed Droplet Digital PCR Assays for the Simultaneous Screening of Major Genetic Alterations in Tumors of the Central Nervous System. Frontiers in Oncology. 10: 579762. PMID 33282733 DOI: 10.3389/fonc.2020.579762 |
0.479 |
|
| 2020 |
Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Bernier V, Laprie A, Supiot S, Leseur J, Habrand JL, Alapetite C, Kerr C, Dufour C, Claude L, Chapet S, ... ... Colin C, et al. Exclusive Hyper-fractionated Radiotherapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the two French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups. International Journal of Radiation Oncology, Biology, Physics. PMID 32768563 DOI: 10.1016/J.Ijrobp.2020.07.2324 |
0.648 |
|
| 2020 |
Appay R, Pages M, Colin C, Jones DTW, Varlet P, Figarella-Branger D. Diffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases. Acta Neuropathologica Communications. 8: 95. PMID 32605662 DOI: 10.1186/S40478-020-00978-7 |
0.566 |
|
| 2019 |
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. PMID 31832685 DOI: 10.1093/Neuonc/Noz124 |
0.703 |
|
| 2019 |
Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, Dehais C, Rech F, Taillandier L, Sanson M, Appay R, Colin C, Figarella-Branger D, Battaglia-Hsu SF, Gauchotte G, et al. Ki-67 and MCM6 labelling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. Brain Pathology (Zurich, Switzerland). PMID 31561286 DOI: 10.1111/Bpa.12788 |
0.558 |
|
| 2019 |
Baeza-Kallee N, Bergès R, Soubéran A, Colin C, Denicolaï E, Appay R, Tchoghandjian A, Figarella-Branger D. Glycolipids Recognized by A2B5 Antibody Promote Proliferation, Migration, and Clonogenicity in Glioblastoma Cells. Cancers. 11. PMID 31466399 DOI: 10.3390/Cancers11091267 |
0.792 |
|
| 2019 |
Soubéran A, Cappaï J, Chocry M, Nuccio C, Raujol J, Colin C, Lafitte D, Kovacic H, Quillien V, Baeza-Kallee N, Rougon G, Figarella-Branger D, Tchoghandjian A. Inhibitor of Apoptosis Proteins Determine Glioblastoma Stem-Like Cells Fate in an Oxygen-Dependent Manner. Stem Cells (Dayton, Ohio). PMID 30920104 DOI: 10.1002/Stem.2997 |
0.782 |
|
| 2019 |
Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. Journal of Neuro-Oncology. PMID 30859482 DOI: 10.1007/S11060-019-03141-Y |
0.637 |
|
| 2019 |
Chanez B, Appay R, Guille A, Lagarde A, Adelaide J, Denicolai E, Campello C, Tchoghandjian A, Petrirena G, Colin C, Barrie M, Baeza-Kallee N, Boucard C, Jiguet-Jiglaire C, Graillon T, et al. Genomic analysis of paired IDHwt glioblastoma (GB) to reveal recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT). Journal of Clinical Oncology. 37: e13535-e13535. DOI: 10.1200/Jco.2019.37.15_Suppl.E13535 |
0.819 |
|
| 2019 |
Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Leseur J, Supiot S, Laprie A, Bernier V, Dufour C, Huchet A, Coche-Dequeant B, Truc G, Vigneron C, Alapetite C, ... ... Colin C, et al. Medulloblastoma Molecular Subgroup and Hyperfractionated Radiation Therapy Alone for Standard Risk Medulloblastoma : Results of the Pool Data of MSFOP 1998 and 2007 Studies International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.600 |
0.613 |
|
| 2018 |
Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathologica Communications. 6: 89. PMID 30193580 DOI: 10.1186/S40478-018-0594-1 |
0.728 |
|
| 2018 |
Appay R, Fina F, Macagno N, Padovani L, Colin C, Barets D, Ordioni J, Scavarda D, Giangaspero F, Badiali M, Korshunov A, M Pfister S, T W Jones D, Figarella-Branger D. Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29802359 DOI: 10.1038/S41379-018-0050-6 |
0.7 |
|
| 2018 |
Macagno N, Vogels R, Appay R, Colin C, Mokhtari K, Küsters B, Wesseling P, Figarella-Branger D, Flucke U, Bouvier C. Grading of Meningeal Solitary Fibrous Tumors/Hemangiopericytomas: Analysis of the Prognostic Value of the Marseille Grading System in a Cohort of 132 Patients. Brain Pathology (Zurich, Switzerland). PMID 29600523 DOI: 10.1111/Bpa.12613 |
0.665 |
|
| 2018 |
Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology. PMID 29522183 DOI: 10.1093/Neuonc/Noy014 |
0.709 |
|
| 2018 |
Tabouret E, Compes P, Etcheverry A, Colin C, Appay R, Cordier N, Chinot OL, Delinguette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Molecular and neuro-radiological characteristics of diffuse grade II and III gliomas involving the insula. Journal of Clinical Oncology. 36: e14050-e14050. DOI: 10.1200/Jco.2018.36.15_Suppl.E14050 |
0.678 |
|
| 2017 |
Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, Chinot O, Figarella-Branger D, Guedj E. IDH mutation is paradoxically associated with higher (18)F-FDOPA PET uptake in diffuse grade II and grade III gliomas. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28293705 DOI: 10.1007/S00259-017-3668-6 |
0.506 |
|
| 2016 |
Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DT, Figarella-Branger D. Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget. PMID 27791984 DOI: 10.18632/Oncotarget.12881 |
0.767 |
|
| 2016 |
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathologica. PMID 27573687 DOI: 10.1007/S00401-016-1611-8 |
0.708 |
|
| 2016 |
Tchoghandjian A, Soubéran A, Tabouret E, Colin C, Denicolaï E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death & Disease. 7: e2325. PMID 27490930 DOI: 10.1038/Cddis.2016.214 |
0.778 |
|
| 2016 |
Mascelli S, Nozza P, Jones DT, Colin C, Pistorio A, Milanaccio C, Ravegnani M, Consales A, Witt O, Morana G, Cama A, Capra V, Biassoni R, Pfister SM, Figarella-Branger D, et al. TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. Oncotarget. PMID 27374106 DOI: 10.18632/Oncotarget.10295 |
0.494 |
|
| 2016 |
Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, et al. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro-Oncology. 18: 888-90. PMID 27175000 DOI: 10.1093/Neuonc/Now085 |
0.495 |
|
| 2016 |
Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, et al. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nature Communications. 7: 11263. PMID 27090007 DOI: 10.1038/Ncomms11263 |
0.554 |
|
| 2016 |
Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, Jünger S, de Paula AM, Bouvier C, Colin C, Jouvet A, Forest F, Andreiuolo F, Quintin-Roue I, Machet MC, Heitzmann A, Milin S, Sevestre H, et al. Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncology. PMID 26984744 DOI: 10.1093/Neuonc/Now025 |
0.753 |
|
| 2016 |
Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D. Molecular heterogeneity of glioblastomas: does location matter? Oncotarget. 7: 902-13. PMID 26637806 DOI: 10.18632/Oncotarget.6433 |
0.794 |
|
| 2015 |
Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, et al. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathology (Zurich, Switzerland). 25: 418-28. PMID 25407774 DOI: 10.1111/Bpa.12227 |
0.596 |
|
| 2015 |
Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, Miquel C, Uro-Coste E, Godfraind C, Lechapt-Zalcman E, Labrousse F, Gauchotte G, Silva K, Jouvet A, Figarella-Branger D, et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathology and Applied Neurobiology. 41: 403-8. PMID 25389051 DOI: 10.1111/Nan.12196 |
0.645 |
|
| 2015 |
Denicolai E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Baeza-Kallee N, Fina F, Chinot OL, Figarella-Branger D. Differential molecular expression profile according to glioblastoma (GB) location. Journal of Clinical Oncology. 33: 2030-2030. DOI: 10.1200/Jco.2015.33.15_Suppl.2030 |
0.792 |
|
| 2014 |
Denicolaï E, Baeza-Kallee N, Tchoghandjian A, Carré M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 5: 10934-48. PMID 25400117 DOI: 10.18632/Oncotarget.2541 |
0.785 |
|
| 2014 |
El Hallani S, Colin C, El Houfi Y, Idbaih A, Boisselier B, Marie Y, Ravassard P, Labussière M, Mokhtari K, Thomas JL, Delattre JY, Eichmann A, Sanson M. Tumor and endothelial cell hybrids participate in glioblastoma vasculature. Biomed Research International. 2014: 827327. PMID 24868550 DOI: 10.1155/2014/827327 |
0.379 |
|
| 2014 |
Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, et al. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology. 16: 1244-54. PMID 24723566 DOI: 10.1093/Neuonc/Nou047 |
0.498 |
|
| 2013 |
Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, Lambert S, Baeza-Kallee N, Fernandez C, Chappé C, André N, Figarella-Branger D. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathologica Communications. 1: 17. PMID 24252689 DOI: 10.1186/2051-5960-1-17 |
0.774 |
|
| 2013 |
Figarella-Branger D, Chappe C, Padovani L, Mercurio S, Colin C, Forest F, Bouvier C. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification]. Bulletin Du Cancer. 100: 715-26. PMID 23831947 DOI: 10.1684/Bdc.2013.1789 |
0.804 |
|
| 2013 |
Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathology (Zurich, Switzerland). 23: 574-83. PMID 23442159 DOI: 10.1111/Bpa.12048 |
0.796 |
|
| 2013 |
Colin C, Padovani L, Chappé C, Mercurio S, Scavarda D, Loundou A, Frassineti F, André N, Bouvier C, Korshunov A, Lena G, Figarella-Branger D. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution. Neuropathology and Applied Neurobiology. 39: 693-705. PMID 23278243 DOI: 10.1111/Nan.12013 |
0.756 |
|
| 2012 |
Padovani L, Colin C, Fernandez C, Maues de Paula A, Mercurio S, Scavarda D, Frassineti F, Adélaïde J, Loundou A, Intagliata D, Bouvier C, Lena G, Birnbaum D, Girard N, Figarella-Branger D. Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities? Current Topics in Medicinal Chemistry. 12: 1683-92. PMID 22978341 DOI: 10.2174/156802612803531450 |
0.772 |
|
| 2012 |
Figarella-Branger D, Bouvier C, De Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P. Molecular genetics of adult grade II gliomas: Towards a comprehensive tumor classification system Journal of Neuro-Oncology. 110: 205-213. PMID 22890969 DOI: 10.1007/S11060-012-0953-X |
0.707 |
|
| 2012 |
Tchoghandjian A, Baeza-Kallee N, Beclin C, Metellus P, Colin C, Ducray F, Adélaïde J, Rougon G, Figarella-Branger D. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. Annals of Surgical Oncology. 19: S608-19. PMID 21989663 DOI: 10.1245/S10434-011-2093-5 |
0.8 |
|
| 2011 |
Metellus P, Coulibaly B, Colin C, Maues de Paula A, Barlier A, Loundou A, Fuentes S, Dufour H, Barrie M, Chinot OL, Ouafik L, Figarella-Branger D. Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2023. PMID 28023844 DOI: 10.1200/Jco.2011.29.15_Suppl.2023 |
0.76 |
|
| 2011 |
Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, Coulibaly B, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot OL, Ouafik L, Figarella-Branger D. IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2078. PMID 28019905 DOI: 10.1200/Jco.2011.29.15_Suppl.2078 |
0.762 |
|
| 2011 |
Figarella-Branger D, Paula AMd, Colin C, Bouvier C. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Revue Neurologique. 167: 683-690. PMID 21889777 DOI: 10.1016/J.Neurol.2011.07.006 |
0.709 |
|
| 2011 |
Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, De Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients Journal of Neuro-Oncology. 105: 591-600. PMID 21643985 DOI: 10.7490/F1000Research.2027.1 |
0.583 |
|
| 2011 |
Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution Annals of Surgical Oncology. 18: 2937-2945. PMID 21479688 DOI: 10.1245/S10434-011-1703-6 |
0.75 |
|
| 2011 |
Metellus P, Voutsinos-Porche B, Nanni-Metellus I, Colin C, Fina F, Berenguer C, Dussault N, Boudouresque F, Loundou A, Intagliata D, Chinot O, Martin PM, Figarella-Branger D, Ouafik L. Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma. European Journal of Cancer (Oxford, England : 1990). 47: 1727-35. PMID 21458987 DOI: 10.1016/J.Ejca.2011.02.021 |
0.517 |
|
| 2010 |
Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M, Figarella-Branger D. Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters. 1: 883-884. PMID 22966399 DOI: 10.3892/Ol_00000156 |
0.494 |
|
| 2010 |
Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathologica. 120: 719-29. PMID 21080178 DOI: 10.1007/S00401-010-0777-8 |
0.757 |
|
| 2010 |
Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, Marie Y, Rickman D, Thomas E, Delattre JY, Honnorat J, et al. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Cancer. 9: 234. PMID 20822523 DOI: 10.1186/1476-4598-9-234 |
0.494 |
|
| 2010 |
Figarella-Branger D, Colin C, Tchoghandjian A, Baeza N, Bouvier C. [Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment]. Neuro-Chirurgie. 56: 441-8. PMID 20817192 DOI: 10.1016/J.Neuchi.2010.07.010 |
0.785 |
|
| 2010 |
El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A, Delattre JY, Maniotis AJ, Sanson M. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain : a Journal of Neurology. 133: 973-82. PMID 20375132 DOI: 10.1093/Brain/Awq044 |
0.36 |
|
| 2010 |
Ayachi IE, Baeza N, Fernandez C, Colin C, Scavarda D, Pesheva P, Figarella-Branger D. KIAA0510, the 3'-untranslated region of the tenascin-R gene, and tenascin-R are overexpressed in pilocytic astrocytomas. Neuropathology and Applied Neurobiology. 36: 399-410. PMID 20202125 DOI: 10.1111/J.1365-2990.2010.01074.X |
0.48 |
|
| 2010 |
Bikeye SN, Colin C, Marie Y, Vampouille R, Ravassard P, Rousseau A, Boisselier B, Idbaih A, Calvo CF, Leuraud P, Lassalle M, El Hallani S, Delattre JY, Sanson M. ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. Cancer Cell International. 10: 1. PMID 20142996 DOI: 10.1186/1475-2867-10-1 |
0.496 |
|
| 2010 |
Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, Ouafik L, Figarella-Branger D. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathology (Zurich, Switzerland). 20: 211-21. PMID 19243384 DOI: 10.1111/J.1750-3639.2009.00269.X |
0.759 |
|
| 2010 |
Metellus P, Nanni-Metellus I, Delfino C, Colin C, Coulibaly B, Fina F, Chinot OL, Figarella-Branger D, Ouafik L. Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study. Journal of Clinical Oncology. 28: 2027-2027. DOI: 10.1200/Jco.2010.28.15_Suppl.2027 |
0.736 |
|
| 2010 |
Metellus P, Coulibaly B, Colin C, Marie Y, Boisselier B, Moktari K, Loundou A, Chapon F, Chinot O, Figarella-Branger D. L’absence de mutation d’IDH identifie une nouvelle entité radio-clinique et moléculaire au sein des gliomes de bas grade (OMS II) Neurochirurgie. 56: 538-539. DOI: 10.1016/J.Neuchi.2010.10.045 |
0.703 |
|
| 2009 |
Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagliata D, Baeza N, Bouvier C, Delfino C, Loundou A, Chinot O, Lah T, Kos J, Martin PM, Ouafik L, et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathologica. 118: 745-54. PMID 19774387 DOI: 10.1007/S00401-009-0592-2 |
0.682 |
|
| 2009 |
Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D. Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain : a Journal of Neurology. 132: 1523-35. PMID 19336457 DOI: 10.1093/Brain/Awp048 |
0.807 |
|
| 2009 |
Hallani SE, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodero M, Chinot O, Thillet J, Hoang-Xuan K, Delattre J-, Sanson M. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma Neurology. 72: 332-336. PMID 19171829 DOI: 10.1212/01.Wnl.0000341277.74885.Ec |
0.329 |
|
| 2008 |
Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C. [Histological and molecular classification of gliomas]. Revue Neurologique. 164: 505-15. PMID 18565348 DOI: 10.1016/J.Neurol.2008.03.011 |
0.822 |
|
| 2007 |
Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, Bouvier C, Calisti A, Tong S, Durbec P, Figarella-Branger D. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathology and Applied Neurobiology. 33: 431-9. PMID 17442061 DOI: 10.1111/J.1365-2990.2007.00829.X |
0.792 |
|
| 2006 |
Fernandez C, Maues de Paula A, Colin C, Quilichini B, Bouvier-Labit C, Girard N, Scavarda D, Lena G, Figarella-Branger D. Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases. Child's Nervous System : Chns : Official Journal of the International Society For Pediatric Neurosurgery. 22: 1603-10. PMID 16951965 DOI: 10.1007/S00381-006-0184-6 |
0.684 |
|
| 2006 |
Figarella-Branger D, Colin C, Chinot O, Nanni I, Baeza N, Fina F, Tong S, Eudes N, Quilichini B, Romain S, Metellus P, Fuentes S, Barrié M, Boucard C, Fraslon C, et al. AP-HM tumour tissue bank: Molecular signature of gliomas | Tumorothèque de l'AP-HM: Cartographie moléculaire des gliomes Medecine/Sciences. 22: 54-59. PMID 16705945 DOI: 10.1051/Medsci/2006221S54 |
0.574 |
|
| 2006 |
Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P, Figarella-Branger D. In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathology and Applied Neurobiology. 32: 189-202. PMID 16599947 DOI: 10.1111/J.1365-2990.2006.00740.X |
0.683 |
|
| 2005 |
Bouvier C, Liprandi A, Colin C, Giorgi R, Quilichini B, Metellus P, Figarella-Branger D. Lack of alkaline phosphatase activity predicts meningioma recurrence. American Journal of Clinical Pathology. 124: 252-8. PMID 16040297 DOI: 10.1309/482Awa3U8Djuexwu |
0.7 |
|
| 2003 |
Bouvier C, Bartoli C, Aguirre-Cruz L, Virard I, Colin C, Fernandez C, Gouvernet J, Figarella-Branger D. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. Journal of Neurosurgery. 99: 344-50. PMID 12924709 DOI: 10.3171/Jns.2003.99.2.0344 |
0.785 |
|
| Show low-probability matches. |